It’s worth mentioning that mGluR5-selective negative allosteric modulators were previously reported to reduce the Aβ oligomers and plaques, and to improve the cognitive function in the APPswe/PS1ΔE9 mouse model of AD [44]. This evidence concerns the gene GRM5 and Alzheimer disease.